Annals of Hematology

, Volume 70, Issue 6, pp 313–318 | Cite as

Long-term therapy with recombinant human erythropoietin (rHu-EPO) in progressing multiple myeloma

  • F. Silvestris
  • A. Romito
  • P. Fanelli
  • A. Vacca
  • F. Dammacco
Original Article

Abstract

Recombinant human erythropoietin (rHu-EPO) is an effective growth factor for erythroid progenitor cells in anemia provoked by several conditions, including bone marrow tumors such as multiple myeloma (MM). We studied a group of 54 patients with MM undergoing second-induction chemotherapy. Thirty of them were randomly assigned to receive rHu-EPO at an initial dosage of 150 units/kg body weight three times a week, increased to 300 units/kg from the sixth week to the end of the 24-week study. Hemoglobin (Hb) levels increased in 77.7% of these patients by the eighth week. In addition, five transfusion-dependent patients in treatment with the VMCP protocol completed the trial without requiring blood supplement after the third month, whereas seven control patients required frequent supplements. Monthly assessment of hematologic parameters demonstrated the ability of rHu-EPO to increase reticulocyte counts, whereas five patients became resistant to the second-induction chemotherapy in apparent concurrence with their rHu-EPO therapy. The response to rHu-EPO in four of the five MM patients receiving cytotoxic protocols combined with α-interferon (α-IFN) included an increase of serum IgM after the third month. This effect was not demonstrable in any other group, including three rHu-EPO-untreated patients undergoing α-IFN + VMCP combined therapy, as well as rHu-EPO-treated patients not receiving a-IFN. Our data suggest that α-IFN plus rHu-EPO treatment in MM patients is effective in restoring normal B cell function. These results may reflect in vivo the modulation of normal human B cells and lymphoblasts by rHu-EPO observed in vitro.

Key words

Anemia α-Interferon Chemotherapy Multiple myeloma rHu-EPO 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Alexanian R, Dimopoulos M (1994) The treatment of multiple myeloma. N Engl J Med 330:484–489PubMedGoogle Scholar
  2. 2.
    Beguin Y, Yerna M, Loo M, Weber M, Fillet G (1992) Erythropoiesis in multiple myeloma: defective red cell production due to inappropriate erythropoietin production. Br J Haematol 82:648–653PubMedGoogle Scholar
  3. 3.
    Beridge MV, Fraser JK, Carter J, Lin FK (1988) Effects of recombinant human erythropoietin on megakaryocytes and on platelet production in the rat. Blood 72:970–977PubMedGoogle Scholar
  4. 4.
    Boelaert J, Cantinieaux B, Hariga C, Fondu PG (1990) Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron overloaded dialysis patients. Nephrol Dial Transplant 5:504–507PubMedGoogle Scholar
  5. 5.
    Camba L, Durie BGM (1992) Multiple myeloma: new treatment options. Drugs 44:170–181PubMedGoogle Scholar
  6. 6.
    Canadian Erythropoietin Study Group (1990) Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. Br Med J 300:573–578Google Scholar
  7. 7.
    Case DC, Sonneborn HL, Paul SD (1986) Phase-II study of rDNA alpha-interferon (Intron A) in patients with multiple myeloma utilizing an escalating induction phase. Cancer Treat Rep 70:1251–1254PubMedGoogle Scholar
  8. 8.
    Chandra M, Clemons GK, McVicar M, Wilkes B, Bluestone PA, Mailloux LU, Mossey RT (1988) Serum erythropoietin levels and hematocrit in end-stage renal disease: influence of the mode of dialysis. Am J Kidney Dis 12:208–213PubMedGoogle Scholar
  9. 9.
    Constanzi JJ, Pollard RB (1987) The use of interferon in the treatment of multiple myeloma. Semin Oncol 14:S2:24–28PubMedGoogle Scholar
  10. 10.
    Creasley AA, Bartholomew JG, Merigan TC (1980) Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon. Proc Natl Acad Sci USA 77:1471–1475PubMedGoogle Scholar
  11. 11.
    Depaoli L, Levis A, Isabella N, Ficara F, Priotto C, Lista P, Foà R, Resegotti L (1993) Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes. Haematologica (Pavia) 78:118–122Google Scholar
  12. 12.
    Dessypris EN, Graber SE, Krantz SB, Stone WJ (1988) Effects of recombinant erythropoietin on the concentration and cycling status of human marrow hematopoietic progenitor cells in vivo. Blood 72:2060–2063PubMedGoogle Scholar
  13. 13.
    Douglas SW, Adamson JW (1975) The anemia of chronic disorders: studies of marrow regulation and iron metabolism. Blood 45:55–65PubMedGoogle Scholar
  14. 14.
    Durie BGM, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer 36:842–854PubMedGoogle Scholar
  15. 15.
    Eschback JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase-I and -II clinical trial. N Engl J Med 316:73–78PubMedGoogle Scholar
  16. 16.
    Grimm PC, Sinai-Trieman L, Sekiya NM, Robertson LS, Robinson BJ, Ettenger RB (1990) Effects of recombinant human erythropoietin in HLA sensitization and cell-mediated immunity. Kidney Intern 38:12–19Google Scholar
  17. 17.
    Hellström E, Birgegärd G, Locker D, Helmers C, Öst Å, Wide L (1991) Treatment of myelodysplastic syndromes with recombinant human erythropoietin. Eur J Hematol 47:355–366Google Scholar
  18. 18.
    Imiela J, Korczak-Kowalska G, Malecki R, Nowaczyk M, Stepien-Sopniewska B, Gorski A (1993) Immunomodulatory action of human recombinant erythropoietin in men. Immunol Lett 35:271–276PubMedGoogle Scholar
  19. 19.
    Jones SS, D'Andrea AD, Haines LL, Wong GG (1990) Human erythropoietin receptor: cloning expression, and biologic characterization. Blood 76:31–35PubMedGoogle Scholar
  20. 20.
    Karnofsky DA, Burchenal JH (1949) The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM (ed) Evaluation of chemotherapeutic agents. Symposium held at the New York Academy of Medicine, New York (1948). Columbia University Press, New York, pp 191–205Google Scholar
  21. 21.
    Kimata H, Yoshida A, Ishioka C, Masuda S, Sasaki R, Mikawa H (1990) Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serumfree medium. Clin Exp Immunol 85:151–156Google Scholar
  22. 22.
    Kimata H, Yoshida A, Ishioka C, Mikawa H (1991) Erythropoietin enhances immunoglobulin production and proliferation by human plasma cells in a serum-free medium. Clin Immunol Immunopathol 59:495–501PubMedGoogle Scholar
  23. 23.
    Ludwig H, Fritz E, Kotzmann H, Höcker P, Gisslinger T, Barnas V (1991) Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693–1699Google Scholar
  24. 24.
    McLauchein P, Alexanian R (1992) Myeloma protein kinetics following chemotherapy. Blood 60:851–855Google Scholar
  25. 25.
    Miller CB, Jones RI, Piantadosi S, Abeloff MD, Spivak J (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689–1692PubMedGoogle Scholar
  26. 26.
    Muirhead N, Hodsman AB (1990) Occult infection and resistance of anemia to rHu-EPO therapy in renal failure. Nephrol Dial Transplant 5:232–234PubMedGoogle Scholar
  27. 27.
    Okuno Y, Takahashi T, Suzuki A, Ichiba S, Nakamura K, Hitomi K, Sasaki R, Imura R (1990) Expression of the erythropoietin receptor on a human myeloma cell line. Biochem Biophys Res Commun 170:1128–1134PubMedGoogle Scholar
  28. 28.
    Oster W, Herrmann F, Gamm H, Zeile G, Lindemann A, Müller G, Brune T, Kraemer HP, Mertelsmann R (1990) Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J Clin Oncol 8:956–962PubMedGoogle Scholar
  29. 29.
    Pecherstorfer M, Schmoranzer F, Vesely M (1990) Erythropoietin in multiple myeloma. Dtsch Med Wochenschr 115:1096–1099PubMedGoogle Scholar
  30. 30.
    Platanias LC, Miller CB, Mick R, Hart RD, Ozer H, McEvilly JM, Jones RJ, Ratain MJ (1991) Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 9:2021–2026PubMedGoogle Scholar
  31. 31.
    Schapira L, Antin JH, Ransil BJ, Antman KH, Eder J, McGarigle CJ, Golberg MA (1990) Serum erythropoietin levels in patients receiving intensive chemotherapy and radiotherapy. Blood 76:2354–2359PubMedGoogle Scholar
  32. 32.
    Schouten HC, Vellenga E, Van Rhenen DJ, De Wolf JTHM, Coppens PJW, Blijham GH (1991) Recombinant human erythropoietin in patients with myelodysplastic syndromes. Leukemia 5:432–436PubMedGoogle Scholar
  33. 33.
    Selbach J, Purea H, Westerhausen M (1989) Interferon alpha 2 B with chemotherapy in advanced or refractory multiple myeloma. Blut 59: S3, 326Google Scholar
  34. 34.
    Spivak JL (1993) Recombinant erythropoietin. Annu Rev Med 44:243–253PubMedGoogle Scholar
  35. 35.
    Van Kamp H, Prinsze-Postema TC, Kluin PM, Den Ottolander GJ, Beverstock GC, Willemze R, Fibbe WE (1991) Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia. Br J Haematol 78:488–493PubMedGoogle Scholar
  36. 36.
    Wahlin A, Holm J (1989) Rapid response to recombinant interferon alpha and high-dose prednisone in multiple drug-resistant multiple myeloma. Eur J Haematol 42:352–354Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • F. Silvestris
    • 1
  • A. Romito
    • 1
  • P. Fanelli
    • 1
  • A. Vacca
    • 1
  • F. Dammacco
    • 1
  1. 1.Department of Biomedical Sciences and Human Oncology Section of Internal Medicine and Clinical OncologyUniversity of BariBariItaly

Personalised recommendations